Flash Finance

Viyash Scientific Limited (VIYASH) — Multibagger Analysis

AI research on 2 Expansion / Order-win announcements by Viyash Scientific Limited since January 2026 — deal magnitude, revenue and EPS impact, execution risk, and the actual return since each announcement measured from the next trading day's open and benchmarked against the Nifty Smallcap 250.

2
Announcements analysed
0
Strong candidates
55/100
Best multibagger score
+10.7%
Best return since call
Viyash Scientific Limited — Stock analysis & AI research Viyash Scientific Limited — Quarterly results & fundamentals Viyash Scientific Limited — Seasonality — best & worst months Viyash Scientific Limited — Technical indicators & charts Viyash Scientific Limited — Technical setup — score, trend, support & resistance Viyash Scientific Limited — Live exchange announcements

Analysts/Institutional Investor Meet/Con. Call Updates

· Expansion · Possible · Drug Manufacturers - Specialty & Generic · score 52/100
Deal
Deal value—
Deal vs businessNo new order; reiteration of FY26 post-merger revenue of 
3,420 Cr (3.5x of pre-merger TTM of 
976 Cr)
Execution period—
Fundamental gradeB
AI projections
Revenue uplift (yr1 / steady)0.0% / 0.0%
EPS uplift0.0%
Upside base / bull / bear15.0% / 40.0% / -25.0%
Horizon12-18 months
Realized market record
Entry — next-day open (26 Jun 2026)₹269.3
Latest close (16 Oct 2026)₹226.0
Return since-16.1%
α vs Smallcap 250-15.9%
Positives
  • Massive scale-up post-merger with revenue reaching 
3,420 Cr and PAT of 
225 Cr in FY26
  • Strong operating leverage with EBITDA margins doubling to over 20% (EBITDA of 
702.5 Cr)
  • Diversified business model across Animal Formulations (45%), API/CDMO (43%), and Human Formulations (12%)
  • Global footprint with 16 manufacturing facilities, including 9 USFDA-approved sites
  • Robust R&D pipeline with over 185 cumulative patents filed and 200+ scientists
Risks
  • Integration risk of 16 global manufacturing facilities across multiple geographies (India, USA, Spain, Turkey, Brazil)
  • High regulatory risk with 9 USFDA-approved sites subject to ongoing compliance and audits
  • Extremely high valuation (79.6x FY26 PAT) leaving little room for execution missteps
  • Messy historical financial data and restatements due to the reverse merger/restructuring process
  • Potential working capital pressure as the company scales up its global CDMO and formulation business
Governance flags
  • Messy financial reporting with massive restatements and missing quarterly data in PIT database
  • Name change and complex reverse merger structure (formerly Sequent Scientific) which complicates historical comparison
Full AI brief

Executive Summary

As of June 25, 2026, Viyash Scientific Limited (formerly Sequent Scientific) is evaluated following its analyst meet update projecting FY26 EBITDA to reach INR 7,025 million post-merger. While the numbers represent a massive fundamental turnaround, our analysis indicates that this catalyst is 100% already priced in, as the actual FY26 results were already reported in detail on May 19 and May 22, 2026. The stock has run up 39% in the last 3 months and trades at a rich valuation of 79.6x FY26 PAT.

1. Ramp-Aware Impact Math & Catalyst Valuation

  • The Catalyst: The June 25, 2026 announcement is an investor presentation outlining the post-merger trajectory. It is not a new order or contract.
  • Prior Disclosures: On May 19, 2026, the company already reported its actual FY26 results: Revenue of 
3,420 Cr and PAT of 
225 Cr (INR 2,246 million). Therefore, the incremental revenue and EPS uplift from this specific announcement is 0%.
  • Pre-Merger vs. Post-Merger Scale: The pre-merger TTM revenue in the database was 
976 Cr with a PAT of 
59 Cr. The post-merger entity has scaled up by ~3.5x in revenue (
3,420 Cr) and ~3.8x in PAT (
225 Cr).
  • Valuation Check: At the current market cap of 
17,913 Cr, the stock trades at 79.6x FY26 PAT (
225 Cr). This is a high multiple that already discounts the immediate merger synergies.

2. Industry Capital Intensity & Growth Character

  • Industry: Drug Manufacturers - Specialty & Generic (API/CDMO & Formulations).
  • Capital Intensity: MEDIUM. Setting up and maintaining 16 global manufacturing facilities (including 9 USFDA-approved sites) requires steady maintenance capex and R&D investment.
  • Execution Difficulty: MEDIUM to HIGH. Integrating 16 facilities across India, USA, Spain, Turkey, and Brazil involves significant regulatory, cultural, and operational challenges. USFDA compliance is a constant risk.
  • Expected Industry CAGR: 10-12% structurally, driven by global outsourcing in CDMO and steady demand for animal health formulations.

3. Multibagger Quality Assessment

  • Earnings Growth & Acceleration: FY26 PAT skyrocketed by 1,324% to 
225 Cr, driven by merger synergies and operating leverage. However, this is a one-time structural jump due to the merger rather than organic run-rate acceleration.
  • Margins: EBITDA margins have doubled from FY24 levels, reaching ~20.5% in FY26.
  • Balance Sheet & Debt: Net Debt/EBITDA has dropped to a comfortable 0.2x, indicating strong cash generation post-merger.
  • Data Messiness: The historical quarterly P&L is highly fragmented and restated, which lowers our analytical confidence in long-term trend forecasting.

4. Calibrated Scenarios (12-18 Months)

  • Base Case (15% Upside): The stock consolidates after its recent run-up. Synergies are steadily realized, and the company maintains its 20%+ EBITDA margin. P/E contracts slightly to ~65x on forward earnings.
  • Bull Case (40% Upside): Cross-selling synergies between Animal and Human formulations exceed expectations. EBITDA margins expand to 22-23%, and the company secures new large-scale CDMO contracts, driving PAT to 
300 Cr+.
  • Bear Case (-25% Downside): Regulatory issues or USFDA warning letters at key sites disrupt supply. Integration friction leads to margin contraction back to 15-16%, causing a sharp de-rating of the multiple to 50x.

5. Verdict Rationale

We classify Viyash Scientific as a POSSIBLE multibagger candidate with a score of 52/100. The structural transformation into a diversified global pharma player with 9 USFDA sites is highly positive. However, the near-term upside is capped because the spectacular FY26 turnaround is already fully priced in, and the stock trades at a premium valuation of nearly 80x trailing earnings. We prefer to wait for 2-3 quarters of post-merger execution consistency before upgrading our conviction.

Analysis as of 2026-06-25 (price ₹269.30) · AI research, not investment advice.
FollowTelegram

Press Release

· Expansion · Possible · Drug Manufacturers - Specialty & Generic · score 55/100
Deal
Deal value—
Deal vs businessDistribution partnership (no upfront value; estimated steady-state revenue of 16% of TTM revenue)
Size vs own revenue0.16×
Execution period3.0 yr
Fundamental gradeC
AI projections
Revenue uplift (yr1 / steady)4.5% / 16.2%
EPS uplift19.2%
Upside base / bull / bear25.0% / 50.0% / -30.0%
Horizon24-36 months
Realized market record
Entry — next-day open (23 Jan 2026)₹204.2
Latest close (16 Oct 2026)₹226.0
Return since+10.7%
α vs Smallcap 250-4.2%
Positives
  • Strategic partnership with Boehringer Ingelheim, a global leader in companion animal health, validating Alivira's distribution network.
  • Entry into the high-margin companion animal segment, which enjoys superior pricing power compared to production animals.
  • Post-merger scale makes Viyash a top 25 global animal health player with operations across multiple geographies.
  • Strong institutional backing with CA Hull Investments (Carlyle) holding a 31.2% stake post-merger.
Risks
  • Significant equity dilution following the allotment of 18.19 crore shares for the merger.
  • Integration risks associated with the composite scheme of amalgamation of Viyash Life Sciences and Sequent Scientific.
  • Messy and incomplete historical financial data makes near-term earnings forecasting highly uncertain.
  • Distribution partnerships typically carry lower operating margins than proprietary manufacturing.
Governance flags
  • Complex composite scheme of amalgamation with multiple entities, leading to significant restructuring and name changes.
  • Incomplete financial reporting with several quarters showing 'None' for revenue and profits.
Full AI brief

Executive Summary

Viyash Scientific Limited (formerly Sequent Scientific) has announced a strategic partnership with Boehringer Ingelheim India to distribute and promote their companion animal portfolio in India through its subsidiary, Alivira Animal Health. While this partnership validates Alivira's distribution capabilities and targets a high-margin, fast-growing segment, the company is currently undergoing a massive corporate transition following its composite merger. The lack of clean historical data and significant equity dilution warrant a cautious, wait-and-watch approach.

1. Ramp-Aware Impact Math

  • TTM Baseline: TTM Revenue is reported at ’154 Cr with a TTM PAT of ’13 Cr. (Note: These numbers likely represent pre-merger standalone or partial figures, as Sequent historically had much larger revenues. However, we must strictly analyze based on the provided point-in-time data).
  • Partnership Potential: No deal value was disclosed. Assuming the addressable companion animal market for these products in India is ’200-300 Cr, Alivira could realistically capture ’25 Cr in annual revenue at steady-state (Year 3).
  • Year 1 Revenue Uplift: We estimate a conservative Year 1 revenue of ’7 Cr (4.5% of TTM revenue) as distribution channels and marketing campaigns are rolled out.
  • Steady-State Revenue Uplift: ’25 Cr (16.2% of TTM revenue) by Year 3.
  • Earnings Impact: Assuming a 10% net profit margin on this distribution business, the steady-state PAT contribution would be ’2.5 Cr. This represents a 19.2% uplift over the TTM PAT of ’13 Cr.
  • Dilution Warning: The company recently allotted 18.19 crore new equity shares to Viyash shareholders, which will significantly dilute EPS in the near term, offsetting the immediate benefits of this partnership.

2. Industry Capital-Intensity & Expected CAGR

  • Capital Intensity: Medium. Distribution partnerships are asset-light, but the broader animal health manufacturing business requires moderate capex for R&D and GMP-compliant facilities.
  • Industry CAGR: The Indian companion animal healthcare market is structurally growing at an estimated 12-15% CAGR, driven by rising pet adoption, urbanization, and increased spending on preventive pet care.

3. Multibagger Quality & Fundamentals

  • Financial Health: The historical financials are highly fragmented and messy due to the recent merger. Multiple quarters are missing ('None'), making trend analysis difficult.
  • Promoter & Institutional Backing: Post-merger, CA Hull Investments (Carlyle Group) holds a 31.2% stake, providing strong institutional governance and strategic direction.
  • Quality Gate: Passed on an informational basis. Although trailing ROCE is unavailable/distorted, the structural growth of the animal health industry and the backing of Carlyle provide a credible path to future value creation.

4. Scenario Analysis

  • Base Case (25% Upside): Successful integration of the merged entities, smooth rollout of the Boehringer Ingelheim portfolio, and steady-state revenue of ’25 Cr achieved in 3 years. EPS dilution is partially offset by synergy benefits.
  • Bull Case (50% Upside): Rapid adoption of premium companion animal products in India, faster-than-expected merger synergies, and margin expansion due to operating leverage.
  • Bear Case (-30% Downside): Integration bottlenecks from the merger, high debt servicing costs, and lower-than-expected distribution margins leading to earnings disappointment.

5. Verdict Rationale

The partnership is a strong qualitative positive, but the massive corporate restructuring, equity dilution, and lack of clean financial history make Viyash a 'POSSIBLE' rather than a 'STRONG_CANDIDATE' multibagger at this stage. Investors should wait for consolidated post-merger balance sheets and quarterly results to assess the true earnings power of the combined entity.

Analysis as of 2026-01-22 (price ₹201.17) · AI research, not investment advice.
FollowTelegram

Verdicts and projections on this page are produced by an AI model from Viyash Scientific Limited's public exchange filings and are not investment advice. "Return since" is measured from the opening price of the next trading day after each announcement to the latest available close, so it reflects a price an investor could actually have paid. See all analysed companies on Multibagger AI.

⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI